| Budget Amount *help |
¥5,330,000 (Direct Cost: ¥4,100,000、Indirect Cost: ¥1,230,000)
Fiscal Year 2014: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2013: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2012: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Outline of Final Research Achievements |
In this study, we tried to improve immune-cell therapy for cancer by improvement of an amplification system of cytotoxic T-cells (CTL) activated with cancer peptide vaccine and, combination with CTL and anticancer drugs.
CTLs were able to induce and expand in efficiently using cancer peptide vaccine as activation antigen. The influence of anticancer drugs for CTLs were tested using CTLs activated with a CMV peptide. Docetaxel, Gemcitabin and Cisplatin did not show any influence for reactivity of CTL, but showed inhibition activity for proliferation. These results showed that Docetaxel, Gemcitabin and Cisplatin were able to use with CTLs for treatment with cancer patients, but not combination with peptide vaccines. Iressa, Sorafenib and 5-FU did not show any influence for reactive activity and proliferation of CTL, and direct cytotoxicity for CTLs. These results indicate that these drugs can be used with CTLs and peptide vaccines for the treatment of cancer patients.
|
